Cargando…
Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586683/ https://www.ncbi.nlm.nih.gov/pubmed/33106185 http://dx.doi.org/10.1186/s13063-020-04811-3 |
_version_ | 1783600049590108160 |
---|---|
author | Deng, Haiping Shu, Yu Lv, Peiran Zhao, Ling Cheng, Ke Zhang, Tingting Song, Yi Yang, Hua Tang, Hong Pei, Jian Shen, Xueyong |
author_facet | Deng, Haiping Shu, Yu Lv, Peiran Zhao, Ling Cheng, Ke Zhang, Tingting Song, Yi Yang, Hua Tang, Hong Pei, Jian Shen, Xueyong |
author_sort | Deng, Haiping |
collection | PubMed |
description | BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA) versus sham acupuncture (SA) for DPN. METHODS/DESIGN: This is a study protocol for a randomized, placebo-controlled clinical trial. A total of 118 patients with DPN will be recruited and randomly assigned in a 1:1 ratio to either the MA group or SA group. All patients will receive 24 sessions over 12 weeks. Participants will complete the trial by visiting the research center at month 6 for a follow-up assessment. The primary outcome is peroneal motor nerve conduction velocity (peroneal MNCV) at week 12 compared with baseline. Secondary outcomes include peroneal motor nerve action potential amplitude (peroneal MNAP) and latent period (peroneal MNLP), sural sensory nerve conduction velocity (sural SNCV), action potential amplitude (sural SNAP) and latent period (sural SNLP), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPG), glycated hemoglobin (HbAlc) at week 12 compared with baseline, Michigan Neuropathy Screening Instrument (MNSI) score and Diabetes Specific Quality of Life scale (DSQL) at week 12 and month 6 compared with baseline. Safety will be assessed during the whole trial. Masking effectiveness will be assessed by patients. DISCUSSION: This trial may provide high-quality evidence for evaluating the efficacy and safety of MA treatment for DPN compared with SA treatment. Results of this study will be published in peer-reviewed journals. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1800020444. First registered on 29 December 2018, retrospectively registered, http://www.chictr.org.cn/showproj.aspx?Proj=31063. |
format | Online Article Text |
id | pubmed-7586683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75866832020-10-27 Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial Deng, Haiping Shu, Yu Lv, Peiran Zhao, Ling Cheng, Ke Zhang, Tingting Song, Yi Yang, Hua Tang, Hong Pei, Jian Shen, Xueyong Trials Study Protocol BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA) versus sham acupuncture (SA) for DPN. METHODS/DESIGN: This is a study protocol for a randomized, placebo-controlled clinical trial. A total of 118 patients with DPN will be recruited and randomly assigned in a 1:1 ratio to either the MA group or SA group. All patients will receive 24 sessions over 12 weeks. Participants will complete the trial by visiting the research center at month 6 for a follow-up assessment. The primary outcome is peroneal motor nerve conduction velocity (peroneal MNCV) at week 12 compared with baseline. Secondary outcomes include peroneal motor nerve action potential amplitude (peroneal MNAP) and latent period (peroneal MNLP), sural sensory nerve conduction velocity (sural SNCV), action potential amplitude (sural SNAP) and latent period (sural SNLP), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPG), glycated hemoglobin (HbAlc) at week 12 compared with baseline, Michigan Neuropathy Screening Instrument (MNSI) score and Diabetes Specific Quality of Life scale (DSQL) at week 12 and month 6 compared with baseline. Safety will be assessed during the whole trial. Masking effectiveness will be assessed by patients. DISCUSSION: This trial may provide high-quality evidence for evaluating the efficacy and safety of MA treatment for DPN compared with SA treatment. Results of this study will be published in peer-reviewed journals. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1800020444. First registered on 29 December 2018, retrospectively registered, http://www.chictr.org.cn/showproj.aspx?Proj=31063. BioMed Central 2020-10-26 /pmc/articles/PMC7586683/ /pubmed/33106185 http://dx.doi.org/10.1186/s13063-020-04811-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Deng, Haiping Shu, Yu Lv, Peiran Zhao, Ling Cheng, Ke Zhang, Tingting Song, Yi Yang, Hua Tang, Hong Pei, Jian Shen, Xueyong Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial |
title | Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial |
title_full | Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial |
title_fullStr | Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial |
title_full_unstemmed | Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial |
title_short | Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial |
title_sort | acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586683/ https://www.ncbi.nlm.nih.gov/pubmed/33106185 http://dx.doi.org/10.1186/s13063-020-04811-3 |
work_keys_str_mv | AT denghaiping acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT shuyu acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT lvpeiran acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT zhaoling acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT chengke acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT zhangtingting acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT songyi acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT yanghua acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT tanghong acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT peijian acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial AT shenxueyong acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial |